Fernando Faglioni Ribas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fernando Faglioni Ribas has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Hueb
Department of Cardiovascular Surgery, Hospital das Clínicas Samuel Libânio (HCSL), Pouso Alegre, MG, Brazil (A.C.H., M.L.J.G.).
1 shared publication - Bianca Meneghini
Division of Cardiovascular Surgery, Instituto do Coração (InCor), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (O.A.V.M., B.M., F.L.d.F., L.R.P.D., L.A.F.L., F.B.J.).
1 shared publication - Bruno Mahler Mioto
Universidade de São Paulo, Brasil
1 shared publication Carlos Vicente Serrano
Atherosclerosis Clinical Unit, Instituto do Coração (InCor), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (C.V.S.J)
1 shared publication- Carlos Vicente Serrano Jr
Universidade de São Paulo, Brasil
1 shared publication - Cibele Larrosa Garzillo
Department of Atherosclerosis, Heart Institute of the University of Sao Paulo, Sao Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (20) , 1988-2000
Off-Pump Versus On-Pump Coronary Artery Bypass Grafting in Prefrail and Frail Patients: 30-Day and 1-Year Outcomes From the FRAGILE Randomized Trial
BACKGROUND: Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. METHODS: This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. RESULTS: A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0–73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94–2.31]; P =0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P =0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively ( P =0.099). CONCLUSIONS: In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02338947.
- 17 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (20) , 1988-2000
Open AccessOff-Pump Versus On-Pump Coronary Artery Bypass Grafting in Prefrail and Frail Patients: 30-Day and 1-Year Outcomes From the FRAGILE Randomized Trial
BACKGROUND: Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. METHODS: This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. RESULTS: A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0–73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94–2.31]; P =0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P =0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively ( P =0.099). CONCLUSIONS: In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02338947.
- Open Access
- 22 March 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eRC0522
Torsades de pointes and myocardial infarction following reversal of supraventricular tachycardia with adenosine: a case report
Adenosine is an antiarrhythmic drug that slows conduction through the atrioventricular node and acts as a coronary blood vessel dilator. This case report highlights two unusual life-threatening events following the use of adenosine to revert supraventricular tachycardia in a structurally normal heart: non-sustained polymorphic ventricular tachycardia and myocardial infarction. A 46-year-old woman presented to the emergency department with a two-hour history of palpitations and was diagnosed with supraventricular tachycardia. Vagal maneuvers were ineffective, and after intravenous adenosine administration, the
- 22 March 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eRC0522
Open AccessTorsades de pointes and myocardial infarction following reversal of supraventricular tachycardia with adenosine: a case report
Adenosine is an antiarrhythmic drug that slows conduction through the atrioventricular node and acts as a coronary blood vessel dilator. This case report highlights two unusual life-threatening events following the use of adenosine to revert supraventricular tachycardia in a structurally normal heart: non-sustained polymorphic ventricular tachycardia and myocardial infarction. A 46-year-old woman presented to the emergency department with a two-hour history of palpitations and was diagnosed with supraventricular tachycardia. Vagal maneuvers were ineffective, and after intravenous adenosine administration, the
- Open Access
- 30 November 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais
Papel do edema miocárdico após procedimentos de revascularização avaliado por ressonância magnética cardíaca
Introdução: Evidências sugerem que o edema miocárdico (EM), observado à ressonância magnética por meio do aumento da intensidade do sinal em sequencias ponderadas em T2, representa uma forma de injúria...
- 30 November 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais
Open AccessPapel do edema miocárdico após procedimentos de revascularização avaliado por ressonância magnética cardíaca
Introdução: Evidências sugerem que o edema miocárdico (EM), observado à ressonância magnética por meio do aumento da intensidade do sinal em sequencias ponderadas em T2, representa uma forma de injúria...
- Open Access
- 3 January 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (1) , e1919666
Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease
Glucose control among patients with diabetes is primarily guided by the periodic assessment of glycated hemoglobin (HbA1c) levels. Strict control of diabetes, indicated by lower HbA1c levels, has been associated with reduced microvascular complications, including nephropathy, retinopathy, and peripheral neuropathy.1-3 Strict control of diabetes is less associated with macrovascular events, such as myocardial infarction (MI) or ischemic stroke. Although some studies4 have shown that lower HbA1c levels were associated with lower rates of cardiovascular mortality and MI, landmark randomized clinical trials5,6 have not found significant decreases in cardiovascular end points with intensive glucose control. Additionally, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial7 was prematurely halted because of higher rates of cardiac mortality in the group of patients with target HbA1c levels lower than 6.0% (to convert to proportion of total hemoglobin, multiply by 0.01).7
- 3 January 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (1) , e1919666
Open AccessAssociation of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease
Glucose control among patients with diabetes is primarily guided by the periodic assessment of glycated hemoglobin (HbA1c) levels. Strict control of diabetes, indicated by lower HbA1c levels, has been associated with reduced microvascular complications, including nephropathy, retinopathy, and peripheral neuropathy.1-3 Strict control of diabetes is less associated with macrovascular events, such as myocardial infarction (MI) or ischemic stroke. Although some studies4 have shown that lower HbA1c levels were associated with lower rates of cardiovascular mortality and MI, landmark randomized clinical trials5,6 have not found significant decreases in cardiovascular end points with intensive glucose control. Additionally, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial7 was prematurely halted because of higher rates of cardiac mortality in the group of patients with target HbA1c levels lower than 6.0% (to convert to proportion of total hemoglobin, multiply by 0.01).7